iBio, Inc. (IBIO) - Dilution Analysis

10-Q filing | 34.5M shares outstanding

8-K filing: iBio, Inc. announced the potential issuance of shares of common stock upon the exercise of outstanding Series G warrants.

S-3 filing: This prospectus relates to the resale from time to time of up to 11,061,738 shares of common stock of iBio, Inc.

10-Q filing | 20.3M shares outstanding

10-K filing | 19.3M shares outstanding

8-K filing: iBio, Inc. entered into an underwriting agreement for the offering, issuance, and sale of pre-funded warrants to purchase 71,540,000 shares of common stock and accompanying Series G warrants to purchase up to 35,770,000 shares of common stock and Series H warrants to purchase up to 35,770,000 shares of common stock at a combined public offering price of $0.699 per Pre-Funded Warrant and accompanying Series G Warrant, expecting gross proceeds of approximately $50 million. ($50.0M proceeds)

S-3 filing: This prospectus relates to the resale from time to time of up to 11,253,370 shares of common stock, par value $0.001 per share of iBio, Inc., that are issuable upon exercise of warrants, held by the Selling Stockholders.

10-Q filing | 9.9M shares outstanding

10-Q filing | 9.1M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 246,087 shares of common stock by a selling stockholder, acquired through an exclusive license agreement. The company will not receive any proceeds from the sale.

10-Q filing | 8.6M shares outstanding

10-K filing | 8.6M shares outstanding

S-3/A filing: The company may offer and sell up to $150,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units described in the prospectus.

S-3 filing: The company may offer and sell up to $150,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units.

8-K filing: iBio CDMO will pay Woodforest National Bank the proceeds of the sale of property under the Purchase and Sale Agreement when received and the Company will issue to Lender a pre-funded warrant for 1,560,570 shares of the Company's common stock.

10-Q filing | 8.5M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 10,574,556 shares of common stock by selling stockholders, including shares issuable upon exercise of pre-funded warrants and Series E common warrants.

8-K filing: iBio, Inc. closed a private placement on April 1, 2024, issuing 2,701,315 shares of common stock, pre-funded warrants to purchase up to 2,585,963 shares, and Series E warrants to purchase up to 5,287,278 shares, for gross proceeds of approximately $15.1 million and net proceeds of approximately $14.1 million. ($15.1M proceeds)

10-Q filing | 3.2M shares outstanding

8-K filing: iBio, Inc. closed a public offering on December 7, 2023, involving the sale of 600,000 shares of common stock and 1,650,000 pre-funded warrants, along with Series C and Series D common warrants, resulting in approximately $4.5 million in gross proceeds. ($4.5M proceeds)

S-1/A filing: The company is offering up to 1,790,281 shares of common stock, Series C common warrants, Series D common warrants, and pre-funded warrants on a best efforts basis.

8-K filing: Stock split 1-for-20 | Outstanding: 27,653,582 → 1,405,036

10-Q filing | 27.7M shares outstanding

S-1 filing: The company is offering shares of its common stock, common warrants, and pre-funded warrants on a best efforts basis.

POS AM filing: This prospectus relates to the offering of common stock issuable upon exercise of warrants.

10-K filing | 27.6M shares outstanding

8-K filing: iBio, Inc. amended the exercise price with certain holders of Series A and Series B Warrants that were acquired from the Company in the underwritten public offering completed in December 2022, lowering the exercise price of the warrants to $0.50 per share.

S-1 filing: The filing is an S-1 registration statement for up to 4,474,945 shares of common stock to be offered to Lincoln Park Capital under a purchase agreement, with the possibility of issuing additional shares up to $10 million.

8-K filing: iBio, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the potential sale of up to $10.0 million of the Company's common stock, and issued 211,473 shares of Common Stock to Lincoln Park as commitment shares.

10-Q filing | 13.2M shares outstanding

10-Q filing | 12.4M shares outstanding

8-K filing: iBio, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC to sell 1,530,769 shares of Common Stock and pre-funded warrants to purchase up to 1,834,616 shares of Common Stock in a firm commitment underwritten offering. ($3.5M proceeds)

10-Q filing | 8.8M shares outstanding

10-K filing | 8.7M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 218,096,000 → 9,006,583

8-K filing: iBio, Inc. acquired RubrYc Therapeutics' assets for 2,558,854 shares of common stock valued at approximately $1,000,000, with potential additional payments of up to $5,000,000 in cash or shares upon achievement of milestones. ($1.0M proceeds)

8-K filing: iBio, Inc. entered into a Series 2022 Convertible Preferred Stock Purchase Agreement to issue 1,000 shares of Series 2022 Convertible Preferred Stock at $0.27 per share and plans to call a special meeting of stockholders to consider a proposal for a 1-for-25 reverse stock split. ($0.0M proceeds)

8-K filing: iBio, Inc. entered into a Purchase Agreement to issue 1,000 shares of Series 2022 Convertible Preferred Stock at $0.27 per share, and plans to seek stockholder approval for a 1-for-25 reverse stock split. ($0.0M proceeds)

10-Q filing | 218.1M shares outstanding

10-Q filing | 217.9M shares outstanding

10-Q filing | 217.9M shares outstanding

10-K filing | 217.9M shares outstanding

8-K filing: iBio, Inc. entered into a series of agreements with RubrYc Theraputics, Inc., including a Collaboration and License Agreement, a Collaboration, Option and License Agreement, and a Stock Purchase Agreement, involving a $5 million investment in RubrYc for preferred stock and exclusive licenses to certain antibodies. ($5.0M proceeds)

10-Q filing | 217.9M shares outstanding

10-Q filing | 216.0M shares outstanding

8-K filing: iBio, Inc. closed an underwritten public offering and issued additional shares to satisfy the underwriter's option exercise, generating total gross proceeds of approximately $37.1 million. ($41.7M proceeds)

8-K filing: iBio, Inc. closed its underwritten public offering of 29,661,017 shares of common stock on December 10, 2020.

8-K filing: iBio, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to issue and sell 29,661,017 shares of common stock at a price of $1.0955 per share, with the underwriter having an option to purchase up to an additional 4,449,152 shares, resulting in net proceeds to the company of approximately $32.3 million. ($32.3M proceeds)

S-3 filing: The filing is an S-3 shelf registration for the offering of common stock, preferred stock, and debt securities with a total proposed amount of $200,000,000.

8-K filing: IBio, Inc. entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. to sell shares of the Company's common stock, and terminated the Equity Distribution Agreement with UBS Securities LLC, having sold 30,184,399 shares for $72 million. ($72.0M proceeds)

10-Q filing | 182.1M shares outstanding

10-K filing | 180.3M shares outstanding

8-K filing: iBio, Inc. reports 174,415,206 shares of common stock outstanding as of August 12, 2020, after Eastern Capital Limited converted 5,785 shares of Series B Preferred Stock into 28,925,000 shares of common stock at a conversion price of $0.20.

8-K filing: iBio, Inc. amended its equity distribution agreement with UBS Securities LLC, increasing the potential sale of common stock to $72,000,000. It also terminated a purchase agreement with Lincoln Park Capital Fund, LLC, after issuing 20,288,840 shares. ($71.53M proceeds)

10-Q filing | 118.4M shares outstanding

8-K filing: iBio, Inc. entered into a purchase agreement to sell 1,000,000 shares of common stock to Lincoln Park Capital Fund, LLC at $1.09 per share for $1,090,000. ($1.09M proceeds)

8-K filing: iBio, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $50,000,000 in shares of common stock to Lincoln Park over a 36-month term, and issued 815,827 shares of common stock to Lincoln Park as consideration for their commitments.

S-3/A filing: The company may from time to time issue up to $100,000,000 in aggregate principal amount of its common stock, preferred stock, warrants and/or units.

S-3 filing: The company is filing an S-3 to register the offering of up to $100,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units.

8-K filing: iBio, Inc. entered into a warrant exchange and amendment agreement with certain holders to exchange warrants to purchase 15,000,000 shares of common stock for 15,000,000 newly-issued shares of common stock and promissory notes in the aggregate principal amount of $3.3 million.

10-Q filing | 76.2M shares outstanding